- About BSMO
- Task Forces
- Website sponsors
- Contact us
Cancer immunotherapy with monoclonal antibodies (mAb’s) targeting the programmed death-1 receptor (PD-1) or its ligand PD-L1 and the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been integrated in the standard of care for many types of cancer and is under investigation for an increasing number of indications.
This class of immune checkpoint inhibitors (ICI’s) is associated with a specific type of treatment related toxicities (immune-related adverse events, irAE). These inflammatory side-effects are more difficult to predict and more variable as compared to toxicities associated with cytotoxic chemotherapy or targeted therapy. Any organ or tissue can be involved. Although some irAEs occur more commonly than others, some can be very infrequent. While early adequate diagnosis and treatment with corticosteroids is able to control irAE in the majority of cases, they have the potential to be life-threatening.
Guidelines for the treatment of irAE have been published in the medical literature and provided by the marketing authority holders of the specific agents. However, a comprehensive description of the clinical symptoms of specific types of irAE and their management, as well as the palliation of long-term sequels is currently not available.
The BSMO therefore has initiated an effort to bring together experts from different subspecialties to build a consensus electronic document to be published on the “ImmunoManager website”. The first objective of this project is to provide comprehensive guidelines on the incidence, symptoms, diagnostic algorithm and treatment for the different types of irAE.
These will be designed to be ready for direct clinical implementation by physicians that consult them through the website. The website will provide case based illustrations for every irAE. A second objective is to organize an electronic forum for the submission and publication of rare or complicated cases of irAE.
All Immunomanger Guidelines are put together by the BSMO Immuno Task Force based on recent publications and clinical experience.
BSMO Immuno task force
Dr. Sandrine Aspeslagh, Institut Bordet
Prof. Jean-François Baurain, UCL
Prof Oliver Bechter, KUL
Dr. Vibeke Kruse, Ugent
Prof. Bart Neijns, VUB
Dr. Andrée Rorive, CHU Liège
BSMO ImmumoManager is sponsored by:
Please contact the members of the BSMO Immuno Task Force via below response form in case of any question or any observed irAE that is not covered in the ImmunoManager.